Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure.

BACKGROUND Asymptomatic ventricular arrhythmias in patients with congestive heart failure are associated with increased rates of overall mortality and sudden death. Amiodarone is now used widely to prevent ventricular tachycardia and fibrillation. We conducted a trial to determine whether amiodarone can reduce overall mortality in patients with congestive heart failure and asymptomatic ventricular arrhythmias. METHODS We used a double-blind, placebo-controlled protocol in which 674 patients with symptoms of congestive heart failure, cardiac enlargement, 10 or more premature ventricular contractions per hour, and a left ventricular ejection fraction of 40 percent or less were randomly assigned to receive amiodarone (336 patients) or placebo (338 patients). The primary end point was overall mortality, and the median follow-up was 45 months (range, 0 to 54). RESULTS There was no significant difference in overall mortality between the two treatment groups (P = 0.6). The two-year actuarial survival rate was 69.4 percent (95 percent confidence interval, 64.2 to 74.6) for the patients in the amiodarone group and 70.8 percent (95 percent confidence interval, 65.7 to 75.9) for those in the placebo group. At two years, the rate of sudden death was 15 percent in the amiodarone group and 19 percent in the placebo group (P = 0.43). There was a trend toward a reduction in overall mortality among the patients with nonischemic cardiomyopathy who received amiodarone (P = 0.07). Amiodarone was significantly more effective in suppressing ventricular arrhythmias and increased the left ventricular ejection fraction by 42 percent at two years. CONCLUSIONS Although amiodarone was effective in suppressing ventricular arrhythmias and improving ventricular function, it did not reduce the incidence of sudden death or prolong survival among patients with heart failure, except for a trend toward reduced mortality among those with nonischemic cardiomyopathy.

[1]  S. Yusuf,et al.  Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study. , 1992, Journal of the American College of Cardiology.

[2]  Bramahn . Singh,et al.  Amiodarone: historical development and pharmacologic profile. , 1983, American heart journal.

[3]  H. Cingolani,et al.  Negative lusitropic effect of DPI 201-106 and E4031. Possible role of prolonging action potential duration. , 1990, Journal of molecular and cellular cardiology.

[4]  J. Cohn,et al.  Current therapy of the failing heart. , 1988, Circulation.

[5]  J. Langberg,et al.  Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation. , 1989, Journal of the American College of Cardiology.

[6]  P. Kligfield,et al.  Arrhythmias in ischemic and nonischemic dilated cardiomyopathy: prediction of mortality by ambulatory electrocardiography. , 1985, The American journal of cardiology.

[7]  D. DeMets,et al.  Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. , 1991, The New England journal of medicine.

[8]  M. Gheorghiade,et al.  Ventricular arrhythmias in severe heart failure: incidence, significance, and effectiveness of antiarrhythmic therapy. , 1985, American heart journal.

[9]  J. Cleland,et al.  Clinical, haemodynamic, and antiarrhythmic effects of long term treatment with amiodarone of patients in heart failure. , 1987, British heart journal.

[10]  J. Cohn,et al.  Vasodilator Therapy of Cardiac Failure , 1977 .

[11]  F. Tristani,et al.  A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. , 1991, The New England journal of medicine.

[12]  S. Hohnloser,et al.  Amiodarone-associated Proarrhythmic Effects: A Review with Special Reference to Torsade de Pointes Tachycardia , 1994, Annals of Internal Medicine.

[13]  M. Moeschberger,et al.  Factors influencing the one-year mortality of dilated cardiomyopathy. , 1984, The American journal of cardiology.

[14]  H. Doval,et al.  Randomised trial of low-dose amiodarone in severe congestive heart failure , 1994, The Lancet.

[15]  Bramahn . Singh,et al.  Choice and chance in drug therapy of cardiac arrhythmias: technique versus drug-specific responses in evaluation of efficacy. , 1993, The American journal of cardiology.

[16]  J. Senges,et al.  Ventricular arrhythmias in idiopathic dilated cardiomyopathy. , 1984, British heart journal.

[17]  M. Pfisterer,et al.  Beneficial effect of amiodarone on cardiac mortality in patients with asymptomatic complex ventricular arrhythmias after acute myocardial infarction and preserved but not impaired left ventricular function. , 1992, The American journal of cardiology.

[18]  J. Johns,et al.  Beneficial effects of low dose amiodarone in patients with congestive cardiac failure: a placebo-controlled trial. , 1989, Journal of the American College of Cardiology.

[19]  P. Deedwania,et al.  Veterans Affairs congestive heart failure antiarrhythmic trial. CHF STAT Investigators. , 1993, The American journal of cardiology.

[20]  M. Packer.  Calcium channel blockers in chronic heart failure. The risks of "physiologically rational" therapy. , 1990, Circulation.

[21]  W. Mckenna,et al.  Prospective, double-blind, placebo-controlled trial of low-dose amiodarone in patients with severe heart failure and asymptomatic frequent ventricular ectopy. , 1991, American heart journal.

[22]  K. Chatterjee.  Editorial comment amiodarone in chronic heart failure , 1989 .

[23]  The CASCADE Study: randomized antiarrhythmic drug therapy in survivors of cardiac arrest in Seattle. CASCADE Investigators. , 1993, The American journal of cardiology.

[24]  T. Meinertz,et al.  Significance of ventricular arrhythmias in idiopathic dilated cardiomyopathy. , 1984, The American journal of cardiology.